Tag: Mirdametinib

As of early 2025, two MEK inhibitor medications have received FDA approval for the treatment of certain neurofibromas. The advent of these drugs has transformed the treatment landscape for individuals with neurofibromatosis type 1 (NF1), offering a targeted, non-surgical option for specific tumor types. This is a significant shift from previous approaches and addresses the key question of **what medication is used to treat neurofibromas?**

Neurofibromatosis type 1 (NF1), a genetic disorder that causes tumors to grow on nerves, affects approximately 1 in every 3,000 people worldwide [1.6.3, 1.6.2]. For those affected, a critical question arises: what is the best medicine for neurofibroma?

Affecting approximately 1 in every 3,000 to 4,000 people, Neurofibromatosis type 1 (NF1) is a genetic disorder that can cause tumors to grow on nerves [1.5.7]. The newest answer to 'What is the new drug for NF1?' is mirdametinib (Gomekli), approved by the FDA in February 2025 [1.2.1].